{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T09:10:39Z","timestamp":1790327439832,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T00:00:00Z","timestamp":1615420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T00:00:00Z","timestamp":1615420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1038\/s41434-021-00249-7","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T19:03:08Z","timestamp":1615489388000},"page":"760-770","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Striatal \u0394FosB gene suppression inhibits the development of abnormal involuntary movements induced by L-Dopa in rats"],"prefix":"10.1038","volume":"28","author":[{"given":"Goichi","family":"Beck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5492-8088","authenticated-orcid":false,"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayoko","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Maral","family":"Mouradian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3010-6343","authenticated-orcid":false,"given":"Stella M.","family":"Papa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,11]]},"reference":[{"key":"249_CR1","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/S1474-4422(10)70218-0","volume":"9","author":"P Calabresi","year":"2010","unstructured":"Calabresi P, Di Filippo M, Ghiglieri V, Tambasco N, Picconi B. Levodopa-induced dyskinesias in patients with Parkinson\u2019s disease: filling the bench-to-bedside gap. Lancet Neurol. 2010;9:1106\u201317.","journal-title":"Lancet Neurol"},{"key":"249_CR2","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1212\/WNL.0000000000000390","volume":"82","author":"PA Lewitt","year":"2014","unstructured":"Lewitt PA, Mouradian MM. Predicting the development of levodopa-induced dyskinesias: a presynaptic mechanism? Neurology. 2014;82:1574\u20135.","journal-title":"Neurology"},{"key":"249_CR3","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00702-017-1744-5","volume":"125","author":"G Beck","year":"2018","unstructured":"Beck G, Singh A, Papa SM. Dysregulation of striatal projection neurons in Parkinson\u2019s disease. J Neural Transm. 2018;125:449\u201360.","journal-title":"J Neural Transm"},{"key":"249_CR4","doi-asserted-by":"publisher","first-page":"6995","DOI":"10.1523\/JNEUROSCI.0852-07.2007","volume":"27","author":"E Santini","year":"2007","unstructured":"Santini E, Valjent E, Usiello A, Carta M, Borgkvist A, Girault JA, et al. Critical involvement of cAMP\/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci. 2007;27:6995\u20137005.","journal-title":"J Neurosci"},{"key":"249_CR5","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1111\/j.1471-4159.2008.05831.x","volume":"108","author":"E Santini","year":"2009","unstructured":"Santini E, Alcacer C, Cacciatore S, Heiman M, Herve D, Greengard P, et al. L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice. J Neurochem. 2009;108:621\u201333.","journal-title":"J Neurochem"},{"key":"249_CR6","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/j.1471-4159.2008.05417.x","volume":"106","author":"AP Nicholas","year":"2008","unstructured":"Nicholas AP, Lubin FD, Hallett PJ, Vattem P, Ravenscroft P, Bezard E, et al. Striatal histone modifications in models of levodopa-induced dyskinesia. J Neurochem. 2008;106:486\u201394.","journal-title":"J Neurochem"},{"key":"249_CR7","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1006\/nbdi.1999.0259","volume":"6","author":"M Andersson","year":"1999","unstructured":"Andersson M, Hilbertson A, Cenci MA. Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson\u2019s disease. Neurobiol Dis. 1999;6:461\u201374.","journal-title":"Neurobiol Dis"},{"key":"249_CR8","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nn1040","volume":"6","author":"B Picconi","year":"2003","unstructured":"Picconi B, Centonze D, Hakansson K, Bernardi G, Greengard P, Fisone G, et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci. 2003;6:501\u20136.","journal-title":"Nat Neurosci"},{"key":"249_CR9","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.neuroscience.2006.09.001","volume":"144","author":"B Valastro","year":"2007","unstructured":"Valastro B, Andersson M, Lindgren HS, Cenci MA. Expression pattern of JunD after acute or chronic L-DOPA treatment: comparison with deltaFosB. Neuroscience. 2007;144:198\u2013207.","journal-title":"Neuroscience"},{"key":"249_CR10","doi-asserted-by":"publisher","first-page":"7335","DOI":"10.1523\/JNEUROSCI.0252-10.2010","volume":"30","author":"X Cao","year":"2010","unstructured":"Cao X, Yasuda T, Uthayathas S, Watts RL, Mouradian MM, Mochizuki H, et al. Striatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movements. J Neurosci. 2010;30:7335\u201343.","journal-title":"J Neurosci"},{"key":"249_CR11","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0006-3223(01)01234-3","volume":"50","author":"PK Tekumalla","year":"2001","unstructured":"Tekumalla PK, Calon F, Rahman Z, Birdi S, Rajput AH, Hornykiewicz O, et al. Elevated levels of DeltaFosB and RGS9 in striatum in Parkinson\u2019s disease. Biol Psychiatry. 2001;50:813\u20136.","journal-title":"Biol Psychiatry"},{"key":"249_CR12","doi-asserted-by":"publisher","first-page":"7344","DOI":"10.1523\/JNEUROSCI.1043-08.2008","volume":"28","author":"W Renthal","year":"2008","unstructured":"Renthal W, Carle TL, Maze I, Covington HE 3rd, Truong HT, Alibhai I, et al. Delta FosB mediates epigenetic desensitization of the c-fos gene after chronic amphetamine exposure. J Neurosci. 2008;28:7344\u20139.","journal-title":"J Neurosci"},{"key":"249_CR13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ejphar.2014.10.034","volume":"753","author":"EJ Nestler","year":"2015","unstructured":"Nestler EJ. FosB: a transcriptional regulator of stress and antidepressant responses. Eur J Pharmacol. 2015;753:66\u201372.","journal-title":"Eur J Pharmacol"},{"key":"249_CR14","doi-asserted-by":"publisher","first-page":"18664","DOI":"10.1073\/pnas.1907810116","volume":"116","author":"G Beck","year":"2019","unstructured":"Beck G, Singh A, Zhang J, Potts LF, Woo JM, Park ES, et al. Role of striatal DeltaFosB in l-Dopa-induced dyskinesias of parkinsonian nonhuman primates. Proc Natl Acad Sci USA. 2019;116:18664\u201372.","journal-title":"Proc Natl Acad Sci USA"},{"key":"249_CR15","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s00702-018-1886-0","volume":"125","author":"MA Cenci","year":"2018","unstructured":"Cenci MA, J\u00f6rntell H, Petersson P. On the neuronal circuitry mediating L-DOPA-induced dyskinesia. J Neural Transm. 2018;125:1157\u201369.","journal-title":"J Neural Transm"},{"key":"249_CR16","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrn2471","volume":"9","author":"P Jenner","year":"2008","unstructured":"Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci. 2008;9:665\u201377.","journal-title":"Nat Rev Neurosci"},{"key":"249_CR17","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.biopsych.2009.04.005","volume":"66","author":"O Berton","year":"2009","unstructured":"Berton O, Guigoni C, Li Q, Bioulac BH, Aubert I, Gross CE, et al. Striatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease. Biol Psychiatry. 2009;66:554\u201361.","journal-title":"Biol Psychiatry"},{"key":"249_CR18","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1523\/JNEUROSCI.2936-19.2020","volume":"40","author":"RC Sellnow","year":"2020","unstructured":"Sellnow RC, Steece-Collier K, Altwal F, Sandoval IM, Kordower JH, Collier TJ, et al. Striatal Nurr1 facilitates the dyskinetic state and exacerbates levodopa-induced dyskinesia in a rat model of Parkinson\u2019s disease. J Neurosci. 2020;40:3675\u201391.","journal-title":"J Neurosci"},{"key":"249_CR19","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/mds.27695","volume":"34","author":"K Steece-Collier","year":"2019","unstructured":"Steece-Collier K, Stancati JA, Collier NJ, Sandoval IM, Mercado NM, Sortwell CE, et al. Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesia. Mov Disord. 2019;34:697\u2013707.","journal-title":"Mov Disord"},{"key":"249_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pneurobio.2008.09.013","volume":"87","author":"A Nadjar","year":"2009","unstructured":"Nadjar A, Gerfen CR, Bezard E. Priming for l-dopa-induced dyskinesia in Parkinson\u2019s disease: a feature inherent to the treatment or the disease? Prog Neurobiol. 2009;87:1\u20139.","journal-title":"Prog Neurobiol"},{"key":"249_CR21","doi-asserted-by":"publisher","first-page":"5077","DOI":"10.1073\/pnas.88.12.5077","volume":"88","author":"J Yen","year":"1991","unstructured":"Yen J, Wisdom RM, Tratner I, Verma IM. An alternative spliced form of FosB is a negative regulator of transcriptional activation and transformation by Fos proteins. Proc Natl Acad Sci USA. 1991;88:5077\u201381.","journal-title":"Proc Natl Acad Sci USA"},{"key":"249_CR22","doi-asserted-by":"publisher","first-page":"8011","DOI":"10.1523\/JNEUROSCI.2079-07.2007","volume":"27","author":"T Carlsson","year":"2007","unstructured":"Carlsson T, Carta M, Winkler C, Bjorklund A, Kirik D. Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson\u2019s disease. J Neurosci. 2007;27:8011\u201322.","journal-title":"J Neurosci"},{"key":"249_CR23","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1523\/JNEUROSCI.15-05-03863.1995","volume":"15","author":"M Olsson","year":"1995","unstructured":"Olsson M, Nikkhah G, Bentlage C, Bjorklund A. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci. 1995;15:3863\u201375.","journal-title":"J Neurosci"},{"key":"249_CR24","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1093\/brain\/123.7.1365","volume":"123","author":"CS Lee","year":"2000","unstructured":"Lee CS, Cenci MA, Schulzer M, Bjorklund A. Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson\u2019s disease. Brain. 2000;123:1365\u201379.","journal-title":"Brain"},{"key":"249_CR25","doi-asserted-by":"publisher","first-page":"e0153789","DOI":"10.1371\/journal.pone.0153789","volume":"11","author":"G Beck","year":"2016","unstructured":"Beck G, Shinzawa K, Hayakawa H, Baba K, Sumi-Akamaru H, Tsujimoto Y, et al. Progressive axonal degeneration of nigrostriatal dopaminergic neurons in calcium-independent phospholipase A2beta knockout mice. PloS One. 2016;11:e0153789.","journal-title":"PloS One"},{"key":"249_CR26","doi-asserted-by":"publisher","first-page":"5868","DOI":"10.1073\/pnas.0801775105","volume":"105","author":"JL McBride","year":"2008","unstructured":"McBride JL, Boudreau RL, Harper SQ, Staber PD, Monteys AM, Martins I, et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci UAA. 2008;105:5868\u201373.","journal-title":"Proc Natl Acad Sci UAA"},{"key":"249_CR27","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/gt.2011.10","volume":"18","author":"JN Martin","year":"2011","unstructured":"Martin JN, Wolken N, Brown T, Dauer WT, Ehrlich ME, Gonzalez-Alegre P. Lethal toxicity caused by expression of shRNA in the mouse striatum: implications for therapeutic design. Gene Ther. 2011;18:666\u201373.","journal-title":"Gene Ther"},{"key":"249_CR28","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/ana.24789","volume":"80","author":"MS Keiser","year":"2016","unstructured":"Keiser MS, Monteys AM, Corbau R, Gonzalez-Alegre P, Davidson BL. RNAi prevents and reverses phenotypes induced by mutant human ataxin-1. Ann Neurol. 2016;80:754\u201365.","journal-title":"Ann Neurol"},{"key":"249_CR29","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.biopsych.2014.07.007","volume":"79","author":"M Engeln","year":"2016","unstructured":"Engeln M, Bastide MF, Toulme E, Dehay B, Bourdenx M, Doudnikoff E, et al. Selective inactivation of striatal FosB\/DeltaFosB-expressing neurons alleviates L-DOPA-induced dyskinesia. Biol Psychiatry. 2016;79:354\u201361.","journal-title":"Biol Psychiatry"},{"key":"249_CR30","doi-asserted-by":"publisher","first-page":"7537","DOI":"10.1523\/JNEUROSCI.1176-08.2008","volume":"28","author":"L Liang","year":"2008","unstructured":"Liang L, DeLong MR, Papa SM. Inversion of dopamine responses in striatal medium spiny neurons and involuntary movements. J Neurosci. 2008;28:7537\u201347.","journal-title":"J Neurosci"},{"key":"249_CR31","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.celrep.2017.12.095","volume":"22","author":"A Singh","year":"2018","unstructured":"Singh A, Jenkins MA, Burke KJ Jr., Beck G, Jenkins A, Scimemi A, et al. Glutamatergic tuning of hyperactive striatal projection neurons controls the motor response to dopamine replacement in Parkinsonian primates. Cell Rep. 2018;22:941\u201352.","journal-title":"Cell Rep"},{"key":"249_CR32","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.biopsych.2008.06.007","volume":"64","author":"SL Teegarden","year":"2008","unstructured":"Teegarden SL, Nestler EJ, Bale TL. Delta FosB-mediated alterations in dopamine signaling are normalized by a palatable high-fat diet. Biol Psychiatry. 2008;64:941\u201350.","journal-title":"Biol Psychiatry"},{"key":"249_CR33","doi-asserted-by":"publisher","first-page":"e12322","DOI":"10.1371\/journal.pone.0012322","volume":"5","author":"E Santini","year":"2010","unstructured":"Santini E, Sgambato-Faure V, Li Q, Savasta M, Dovero S, Fisone G, et al. Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia. PLoS ONE. 2010;5:e12322.","journal-title":"PLoS ONE"},{"key":"249_CR34","doi-asserted-by":"publisher","first-page":"8965","DOI":"10.1523\/JNEUROSCI.20-24-08965.2000","volume":"20","author":"J Chen","year":"2000","unstructured":"Chen J, Zhang Y, Kelz MB, Steffen C, Ang ES, Zeng L, et al. Induction of cyclin-dependent kinase 5 in the hippocampus by chronic electroconvulsive seizures: role of [Delta]FosB. J Neurosci. 2000;20:8965\u201371.","journal-title":"J Neurosci"},{"key":"249_CR35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/ana.20296","volume":"57","author":"I Aubert","year":"2005","unstructured":"Aubert I, Guigoni C, Hakansson K, Li Q, Dovero S, Barthe N, et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol. 2005;57:17\u201326.","journal-title":"Ann Neurol"},{"key":"249_CR36","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.nbd.2006.11.001","volume":"25","author":"WL Kuan","year":"2007","unstructured":"Kuan WL, Lin R, Tyers P, Barker RA. The importance of A9 dopaminergic neurons in mediating the functional benefits of fetal ventral mesencephalon transplants and levodopa-induced dyskinesias. Neurobiol Dis. 2007;25:594\u2013608.","journal-title":"Neurobiol Dis"},{"key":"249_CR37","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1002\/ana.24375","volume":"77","author":"LF Potts","year":"2015","unstructured":"Potts LF, Park ES, Woo JM, Dyavar Shetty BL, Singh A, Braithwaite SP, et al. Dual kappa-agonist\/mu-antagonist opioid receptor modulation reduces levodopa-induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease. Ann Neurol. 2015;77:930\u201341.","journal-title":"Ann Neurol"},{"key":"249_CR38","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1212\/WNL.50.5.1323","volume":"50","author":"L Verhagen Metman","year":"1998","unstructured":"Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson\u2019s disease. Neurology. 1998;50:1323\u20136.","journal-title":"Neurology"},{"key":"249_CR39","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/00002826-200003000-00004","volume":"23","author":"BJ Snow","year":"2000","unstructured":"Snow BJ, Macdonald L, McAuley D, Wallis W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson\u2019s disease: a double-blind, placebo-controlled study. Clin Neuropharmacol. 2000;23:82\u20135.","journal-title":"Clin Neuropharmacol"},{"key":"249_CR40","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/mds.27131","volume":"32","author":"W Oertel","year":"2017","unstructured":"Oertel W, Eggert K, Pahwa R, Tanner CM, Hauser RA, Trenkwalder C, et al. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson\u2019s disease (EASE LID 3). Mov Disord. 2017;32:1701\u20139.","journal-title":"Mov Disord"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-021-00249-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-021-00249-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-021-00249-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T00:04:57Z","timestamp":1639613097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-021-00249-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,11]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["249"],"URL":"https:\/\/doi.org\/10.1038\/s41434-021-00249-7","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,11]]},"assertion":[{"value":"22 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MMM is a founder of MentiNova, Inc. The remaining authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}